Take Action:

1. Stay Informed – sign up for NJ Vaccine Science action alerts via email, check our Advocacy Home page and our Blog for action items, follow us on Twitter, and like us on Facebook.


2. Call and Email your Senator and Assemblymembers – ask them to oppose bill S902/A969. Use this link to find your representatives’ phone number and send them a message.


3. Call and Email the Bill Sponsors: Senate President Sweeney: sensweeney@njleg.org / 856-251-9801; Assemblyman Conway  asmconway@njleg.org / (856) 461-3997


If you live in Legislative District 11 sign our D11 Petition to protect NJ’s RE. 

Contact NJ Vaccine Science at:


All information, data and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advise. The decision to vaccinate and how you implement that decision is yours and yours alone. You are encouraged to consult with your medical professional and legal adviser.

Measles & Herd Immunity

Measles Death Rates:

Herd Immunity

  • After herd immunity and subsequenct eradiation was not obtained via the measles vaccination program by 1978, the CDC set a goal to eliminate measles from the United States by 1982. This was primarily due to the understanding that herd immunity does not apply to vaccines, but only natural immunity. Hence eradication efforts were abandon in the US. (https://www.cdc.gov/measles/about/history.html)
  • In the 1990’s measles was still not eradicated or eliminated. Poland and Jacobson, (1994) discussed the limitations of the 1-dose vaccines concluding, “The apparent paradox is that as measles immunization rates rise to high levels in a population, measles becomes a disease of immunized persons. Because of the failure rate of the vaccine and the unique transmissibility of the measles virus, the currently available measles vaccine, used in a single-dose strategy, is unlikely to completely eliminate measles. The long-term success of a two-dose strategy to eliminate measles remains to be determined.” (https://www.ncbi.nlm.nih.gov/pubmed/8053748)
  • Measles was finally declared eliminated (absence of continuous disease transmission for greater than 12 months) from the US in 2000 although there were 86 confirmed cases that year. (https://www.cdc.gov/measles/about/history.html)
  • In 2012 Poland and Jacobson addressed the “Re-Emergence of Measles in Developed Countries” despite the implementation of the 2-dose vaccination. Key points from their study include (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905323/)
  • “Multiple studies demonstrate that 2–10% of those immunized with two doses of measles vaccine fail to develop protective antibody levels, and that immunity can wane over time and result in infection (so-called secondary vaccine failure) when the individual is exposed to measles.”
  • “For example, during the 1989–1991 U.S. measles outbreaks 20–40% of the individuals affected had been previously immunized with one to two doses of vaccine” and in the October 2011 outbreak in Canada, over 50% of the 98 individuals had received two doses of measles vaccine.”
  • “This leads to a paradoxical situation whereby measles in highly immunized societies occurs primarily among those previously immunized.”
  • “Our current tool for prevention has limitations that increasingly look to be significant enough that sustained elimination, much less eradication, are unlikely. Perhaps it is time to consider, in earnest, the development of the next generation of measles vaccines.”

Finally, it has been shown that during outbreaks some infected individuals developed measles as a result of vaccination. This infection is called a “vaccine reaction” but doctors can not differentiate between the “vaccine reaction” and a wild Measles infection without genetic testing. (https://jcm.asm.org/content/jcm/55/3/735.full.pdf)

Sign Up for Email Action Alerts

* indicates required